Published in Vaccine Weekly, January 17th, 2007
The company also continues to expand development of the semen sexing technology, has acquired the urokinase manufacturing facility from Merck KgaA, and laid additional groundwork for building value in the vaccine technology. Net loss for fiscal 2006 was $2,092,022 or 6 cents per share, compared to $125,526 or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.